Agenus vs Beam Therapeutics
Beam Therapeutics is the larger business, with $140m of revenue in fiscal 2025 against $114m for Agenus (1.2 times as much). Beam Therapeutics grew faster (120.0% against 10.4%). Agenus kept more of each dollar of sales as profit: a net margin of -0.1% against -57.2%.
| Latest fiscal year | AgenusAGEN, 2025 | Beam TherapeuticsBEAM, 2025 |
|---|---|---|
| Revenue | $114m | $140m |
| Revenue growth | 10.4% | 120.0% |
| Net income | −$101,000 | −$80.0m |
| Operating margin | -17.7% | -274.6% |
| Net margin | -0.1% | -57.2% |
| Return on equity | — | -8.1% |
| Free cash flow | −$77.2m | −$360m |
| Cash | $3.0m | $295m |
| Total debt | $45.5m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 81 | 511 |
| Market value | $284m | $2.74bn |
| Price vs our value range | — | — |
| Moat score | 34 (Weak) | 9 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 31 sales |